ECE2020 Audio ePoster Presentations Pituitary and Neuroendocrinology (217 abstracts)
Introduction: Non-functioningpituitary adenomas (NFPAs) are of benign nature but a sizeable number of NFPAs show aggressive features. Surgery is not always effective in treating NFPAs and thus other therapeutic options are needed. Previous studies have reported that NFPAs express somastostatin receptors (SSTRs) and dopamine receptors (DRDs).
Aim: To systematically analyze the expression of SSTRs and DRDs in a large cohort of clinically well-characterized patients with NFPAs and analyze their potential association with relevant clinical and molecular aggressive features.
Methods: Retrospective study with 113 patients that underwent transsphenoidal surgery in our center. Relevant clinical variables including invasion, surgical cure, recurrence and histological subtype were obtained to analyze potential associations between these variables and DRD and SSTR expression. Real-time quantitative PCR (qPCR) was used to evaluate SSTT and DRD expression. SSTRs was also by immunohistochemistry (IHQ) in. Histological markers E-cadherin, Ki-67 and p53 were also analyzed by IHQ.
Results: As assessed by qPCR, SSTR3 was the predominant SSTR subtype detected, followed by SSTR2, SSTR5, and SSTR1. A similar expression pattern was observed by IHQ. 84% of NFPAs showed elevated SSTR3 levels and 27% of NFPAs showed elevated SSTR2 expression levels. However, only 11% of NFPAs showed high SSTR5 levels. Regarding DRD expression, DRD2 was the predominant DRD subtype, followed by DRD4, DRD5, and DRD1. Only a minor portion of NFPAs displayed substantial Ki67 and p53 levels. No significant associations between SSTR and DRD expression and tumor size, invasion, cure after surgery, E-cadherin, Ki67 and p53 levels.
Conclusions: No associations between SSTR and DRD expression and clinical and molecular aggressive features were found in NFPAs. A notable number of NFPAs displayed substantial SSTR2 and SSTR5 levels providing a rationale for the potential use of SSTR2 and SSTR5 agonists in these groups of NFPAs.
Sources of Research Support
Spanish Ministry of Health, ISCIII co-funded with Fondos FEDER (PI16/00175) and Novartis Oncology Spain.
05 Sep 2020 - 09 Sep 2020